Manipulation of the NO/cGMP pathway does not affect the temperature sensitivity of swim cycle frequency
| n | Regressionslope(Hz/°C) | Regressionintercept(Hz) | |||
|---|---|---|---|---|---|
| Mean | SE | Mean | SE | ||
| Control | 18 | 0.72 | 0.07 | −0.34 | 1.50 |
| SNAP | 5 | 0.57 | 0.16 | 0.46 | 3.53 |
| cGMP | 5 | 0.72 | 0.10 | 1.05 | 2.33 |
| CPTIO | 7 | 0.74 | 0.09 | −1.45 | 2.09 |
| l-NAME | 9 | 0.62 | 0.04 | 2.13 | 0.80 |
| ODQ | 7 | 0.74 | 0.06 | −0.69 | 1.20 |
Pharmacological activation (8-bromo-cGMP and SNAP) and inhibition (CPTIO, l-NAME, ODQ) of the NO/cGMP pathway had no effect relative to control on the slope or the intercept of the linear regression fitted to the relationship between increasing temperature and swim cycle frequency. Average rhythm frequency of sequences with 10–50 swim cycles (fewer cycles at higher temperatures as episode durations decreased) were calculated at three to five different temperatures during the increasing temperature ramp, and the data were fitted with a linear regression using a least-squares procedure. See Materials and Methods for drug description.